Influence of Soy Lecithin Administration on Hypercholesterolemia by Mourad, Amouni Mohamed et al.
Hindawi Publishing Corporation
Cholesterol
Volume 2010, Article ID 824813, 4 pages
doi:10.1155/2010/824813
Clinical Study
Inﬂuenceof Soy Lecithin Administration on
Hypercholesterolemia
AmouniMohamed Mourad,1,2,3 Ederde Carvalho Pincinato,3 PriscilaGavaMazzola,4
Maricene Sabha,4 andPatricia Moriel4
1Department of Pharmacy, Camilo Castelo Branco University, Rua Carolina Fonseca 584-Itaquera, 08230-030 S˜ ao Paulo, SP, Brazil
2Department of Pharmacy, Santo Amaro University, R Isabel Schmidt 339, 04743-030 S˜ ao Paulo, SP, Brazil
3Health and Biological Sciences Department, Mackenzie Presbiterian University, Rua da Consolac ¸˜ ao 896, Campus S˜ ao Paulo,
01302-907 S˜ ao Paulo, SP, Brazil
4Department of Clinical Pathology, Faculty of Medical Sciences, State University of Campinas (FCM-Unicamp),
Rua Tess´ alia Vieira de Camargo 126, Campinas-S˜ ao Paulo, P.O. Box 6111, 13083-970 S˜ ao Paulo, SP, Brazil
Correspondence should be addressed to Patricia Moriel, morielpa@fcm.unicamp.br
Received 24 July 2009; Accepted 4 October 2009
Academic Editor: W. Gibson Wood
Copyright © 2010 Amouni Mohamed Mourad et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Recent studies suggest that lecithin-rich diet can modify cholesterol homeostasis and hepatic lipoprotein metabolism. Considering
the phytotherapeutic impact of lecithin, this work hypothesizes that lecithin administration in hypercholesterolemic patients
may reduce cholesterol concentrations by increasing biliary secretion. Total cholesterol and LDL were evaluated after soy lecithin
administration in hypercholesterolemic patients. One soy lecithin capsule (500mg/RP-Sherer) was administrated daily. One-two
months before the treatment beginning, blood samples were collected for total lipids and cholesterol fractions analysis. The results
showedareductionof40.66%and42.00%intotalcholesterolandof42.05%and56.15%inLDLcholesterolaftertreatmentforone
and two months, respectively. A signiﬁcant reduction in total cholesterol and LDL-cholesterol concentrations was observed during
the ﬁrst month of treatment, suggesting that the administration of soy lecithin daily may be used as a supplemental treatment in
hypercholesterolemia.
1.Introduction
Lipid metabolism studies include a vision for the lipoprotein
structure,function,andadescriptionofthelipidmetabolism
forms, indicating that the dyslipidemias are important risk
factors in the context of cardiovascular disease and that
appropriate intervention can have a signiﬁcant impact on
clinical treatment [1].
Atherosclerosis, the most serious cardiovascular disease,
may aﬀect individuals at an early age (20–29 years). One of
the disease symptoms is greasy striations, and its evolution
depends on several factors, such as heredity addition to
the diet, stress, and aging resulting from vascular serious
imbalances. The relationship between hypercholesterolemia
and coronary atherosclerosis disease has been demonstrated
in many clinical trials [2, 3]. Moreover, the reduction in
the number of events and mortality or coronary disease,
interruption, or even the decline in atherosclerotic disease by
plasma cholesterol-lowering drugs has also been reported by
numerous studies [4, 5].
One of dietary risk factors for dyslipidemias and athero-
genesis is the deﬁciency in the antioxidant intake, such
as selenium [6], vitamin E [7], in addition to the low
consumption of unsaturated fats [8, 9]a n dﬁ b e r[ 10]. More
recently, it has been suggested that antioxidant substances
are capable of reversing endothelial dysfunction caused by
hypercholesterolemia[11–13]andalsoreducethenumberof
coronary events [14], although their use in medical practice
still needs more conclusive information.
Considering the high cost of drugs to reduce the plasma
cholesterol and the prospect of their prolonged use, patients
have relied on alternative treatments for the control of2 Cholesterol
hypercholesterolemia [15, 16]. These treatments have been
used in an empirical way by the population in general
due to the lack of methodologies that allows more reliable
conclusions.
Recent studies suggest that a lecithin enriched diet
can modify the cholesterol homeostasis and lipoprotein
metabolism. Lecithin diet modiﬁes the cholesterol home-
ostasis in the liver, increasing the activity of HMG-CoA
reductase and cholesterol 7 alpha-hydroxylase, and decreas-
ing the microsomal ACAT activity [17].
One of the most spectacular properties of lecithin is
its ability to reduce the excess of LDL cholesterol. It also
promotes the synthesis in the liver of great amount of HDL,
the beneﬁcial cholesterol [18].
Bile acid secretion with high levels of cholesterol and
phospholipids is encouraged by lecithin-rich diets when
compared with diets without lecithin [17]. Therefore, this
study evaluates hypercholesterolemic eﬀect of soy lecithin on
patients with pure or combined hypercholesterolemia.
2.MaterialsandMethods
Volunteers (n = 30) were chosen from a group previ-
ously diagnosed with hypercholesterolemia. Placebo cap-
sules, containing 500mg of soy oil and 500mg soy lecithin
capsules (22% phospholipid (phosphatidiletanolamine), 10%
triacylglycerol, and 68% phosphatidylcholine), were kindly
donated by RP-Sherer (Brazil). Blood was collected using
Vacuttainer System (Bd, Brazil). Analytical determinations
wereperformedusingcommercialenzymatickitsdonatedby
Labtest (Brazil). Statistical analysis were done using Sigma
Stat and the graphs were built in Microsoft Excel software.
2.1. Patients. Thirty volunteers (58–70 years old) were
selected for administration of lecithin. The groups were
chosen from patients diagnosed with hypercholesterolemia,
participants of a project at the University Camilo Castelo
Branco (Unicastelo, SP, Brazil). These voluntary patients
werepreviouslyinformedabouttheuseofbiologicalmaterial
to carry out the work. The project was approved by the
Ethics Committee of the Faculty of Medical Sciences, State
University of Campinas under the protocol number 792/08.
Every volunteer was given one capsule (n = 20) of
500mg soy lecithin daily and placebo group received one
capsule placebo. One and two months after treatment with
beginning, the blood samples were withdrawn and the lipid
proﬁle was performed.
This was a double-blind study, in which only one person
in the group knew the patients who received placebo or soy
leciythin capsule; after the data analysis, it was allowed access
to the primary research groups.
Blood was collected in tubes for serum obtention;
serum was separated by centrifugation at 2500 rpm for 10
minutes. Serum samples were stored in a freezer (20
◦C)
until the determination completion. The volume of blood
required to perform the analysis was 10mL per withdrawn.
For placebo inﬂuence determination blood was withdrawn
before and two months after administration. Patients taking
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Figure 1: Total cholesterol (CH, mg/dL) and cholesterol concen-
tration in lipoproteins (mg/dL) before and 2 months after placebo
administration.The errorbars represent statisticalsigniﬁcance (P<
.001).
soy lecithin capsules had blood withdrawn before and after
the administration (one and two months).
2.2. Lipid Determination. Total cholesterol and triglyceride
concentrations in the plasma were determined by enzymatic
methods, using commercial reagents (Labtest diagnostics,
Brazil).
The HDL cholesterol level was also determined by an
enzymatic method (Labtest diagnostics, Brazil), after the
precipitation of LDL and VLDL fractions. The Friedewald
equation (1), below, was used to obtain the concentration of
LDL cholesterol [19]:
ChLDL = ChTotal −(ChVLDL +C h HDL),( 1 )
where Ch stands for cholesterol and ChVLDL represents
triglycerides divided by ﬁve.
2.3.StatisticalAnalysis. Resultswerecalculatedusingaverage
± standard deviation. The statistical analysis, which was
consideredsigniﬁcant,usedthepairedt-testoftheSigmaStat
software (P<. 001). The graphs were built in Microsoft Excel
software.
3. Results and Discussion
Patients who took placebo capsules showed no diﬀerences in
lipid proﬁle after two months of administration (Figure 1),
total cholesterol was reduced in 11.4%, but this decrease is
not statically signiﬁcant.
For patients taking soy lecithin capsules signiﬁcant
decrease in the total cholesterol concentration and in HDL
cholesterol during the ﬁrst and the second months of
administration suggests that the administration time did not
inﬂuence the results (Figure 2). Also, triglyceride concentra-
tion did not change as seen in relation to cholesterol (data
not shown).
Figure 2 also shows the concentration of lipoprotein
cholesterol, showing a signiﬁcant reduction in the LDL
cholesterol concentration after administration of soy lecithin
capsules, which was not dependent on the administration
time.Cholesterol 3
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Figure 2: Total cholesterol (CH, mg/dL) and cholesterol concen-
tration in lipoproteins (mg/dL) in serum before and after the ﬁrst
and the second months of lecithin administration. ∗ Signiﬁcant in
relation to the period before treatment.
Scientiﬁc community believes that the cholesterol con-
centration is a risk factor of cardiovascular disease. It
was observed that a decrease of 10% in cholesterol is
associated with a 27% reduction in cardiovascular disease
risk [20]. The main determinants of plasma cholesterol are
saturatedfattyacidspolyunsaturatedanddietarycholesterol.
Plasma cholesterol can be further reduced by speciﬁc dietary
supplements, such as ﬁber, garlic, and ﬁsh oils [21].
Thus, many scientists have explored the possibility of
increasing hypocholesterolemic components of foods; recent
studies have shown that soy protein and soy sterols have
hypocholesterolemic eﬀect [22, 23].
In this work, soy lecithin eﬀect on the serum cholesterol
concentration was evaluated. The results showed a decrease
of 40.65% and 42.60% in total cholesterol and 42.65%
and 56.11% in LDL cholesterol, one and two months after
administration, respectively. The results of this study are in
line with studies of soy protein as a whole; there is no work
in literature on the isolated eﬀect of lecithin.
Soybeanpresentsanumberofadvantagescomparedwith
other sources of vegetable protein [24]. It has high-protein
content (38%–42%) of low cost and high quality as well as
isoﬂavones that help in reducing blood cholesterol. The daily
intake of 25 grams of soy protein dramatically reduced the
total cholesterol over a period of approximately three weeks,
that is, one month after treatment beginning. It was also
shown that this eﬀect was not dependent on time, since there
was no increase two months after the treatment end. The
dailyintakeofsoyproteinmayreducetheLDLconcentration
by 30%, while occurs a stimulus for the HDL production
[25, 26].
Soybean protein increases the cholesterol-lowering
eﬀects of plant sterols on rats fed cholesterol; the
combination of plant sterols and soy protein increases
fecal neutral sterols and bile acid excretion compared with
the sterol and soy protein alone; therefore, the combination
of sterol and soy protein shows a more ostensible decrease in
plasma lipids than the isolated ingredients [27].
A decrease in the cholesterol intestinal absorption and
an increase in the bile acid excretion have been suggested as
possible mechanisms for the eﬀects in the reduction of lipids
by soy protein [28].
Jiang et al. [29] demonstrated the inhibition of choles-
terol absorption in diets rich in phosphatidylcholine. This
study suggests that the high degree of saturation of acyl
groups of the soybean phosphatidylcholine decreases the
cholesterol intestinal absorption.
Lecithin is one of the nature elements that have dispers-
ing properties. That is why it can emulsify fat, avoiding its
absorption. Lecithin is capable of reducing LDL-cholesterol.
It also promotes the HDL-cholesterol synthesis [27]. In addi-
tion to be used to help reduce cholesterol and triglycerides
and protect the liver in the prevention of kidney stone
formation, it is used as a tonic for the nervous system and
brain activities. The Food and Drug Administration-(FDA)
USA,andtheWorldFederationofCardiologyrecommended
theuseof25gramsperdayofsoyprotein,whichcorresponds
to approximately 60g of soybeans for cardiovascular disease
prevention. However, it is not yet clear which components of
soy are responsible for their antiatherogenic purposes.
Recentstudiessuggestthatalecithin-richdietcanmodify
the cholesterol homeostasis and lipoprotein metabolism in
liver. Lecithin diet modiﬁes the cholesterol homeostasis in
the liver, increasing the HMG-CoA reductase and alpha 7
hydroxylase cholesterol activities and decreasing the micro-
somal ACAT activity. The LDL concentration and size are
also signiﬁcantly reduced and the bile acid pool and bile lipid
secretion are increased [17].
4. Conclusion
This work suggests that soy lecithin-rich diets can be used
as an adjunct in the treatment of hypercholesterolemia;
however, further works with a large number of patients
should be carried out towards ﬁnding the ideal dose-
response.
Lecithin-rich diets can stimulate the fatty acid secretion
with high levels of cholesterol and phospholipids when com-
pared with diets without lecithin, considering the lecithin
performance as phytotherapic, with a large spectrum of
activity. The results showed signiﬁcant reduction in the con-
centration of total cholesterol and LDL-cholesterol during
the ﬁrst month, suggesting that the daily administration
of lecithin capsule could be used as an adjuvant treatment
in hypercholesterolemia, possibly by reducing the intestinal
absorption or by the increased secretion of bile acids with
high levels of cholesterol and phospholipids.
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